 |
More: American College of Cardiology (ACC) 57th Annual Scientific Session ACC 2008: The Future of Managing Dyslipidemia CME/CE March 29, 2008 - April 1, 2008, Chicago, Illinois Author Information and Disclosures This activity is not sanctioned by, nor a part of, the American College of Cardiology.
Release Date: May 22, 2008; Valid for credit through May 22, 2009 | Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 1.5 nursing contact hours (1.5 contact hours are in the area of pharmacology);
Pharmacists - 1.5 ACPE continuing education credits for pharmacists (0.15 CEUs) | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME/CE Activity- What to Add to a Statin: New Lipid-Regulating Therapies Continue in DevelopmentMichael H. Davidson, MD, FACC, FACP; Linda Brookes, MScACC.08: Now that statins are widely used as standard-of-care, attention is focusing on their shortcomings -- will these new agents that combine with statins to improve efficacy be the next advance?
- Improving Adherence to Niacin TherapyMichael H. Davidson, MD, FACC, FACP; Linda Brookes, MScACC.08: Most clinicians know about the virtues of niacin -- and about the flushing that limits patient adherence. Will a new PGD2 receptor 1 antagonist prove the adjunct that curtails the side effect?
Legal DisclaimerThe materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American College of Cardiology. These materials and the related activity are not sanctioned by the American College of Cardiology or the commercial supporter of the conference and do not constitute an official part of that conference. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Recognize the spectrum of dyslipidemia etiologies and how the individual components contribute to raising cardiovascular risk
- Examine the overall pharmacotherapy armamentarium for treating dyslipidemia, including new classes and combinations
of therapies that are under active development
- Discuss current and future methods for achieving effective therapeutic regimens with extended-release niacin, alone and in combination
- Review safety data on novel agents used for the management of dyslipidemia
Authors and Disclosures Michael H. Davidson, MD
Disclosure: Michael H. Davidson, MD, has disclosed that he has received research grants from Abbott Laboratories, AstraZeneca, Bristol-Myers Squibb, Kos Pharmaceuticals, Merck, Merck/Schering-Plough, Pfizer, Inc., Novartis, Reliant Pharmaceuticals, Inc., Roche Pharmaceuticals, Sankyo Pharma, and Takeda Pharmaceuticals. He has served as a consultant for Abbott Laboratories, AstraZeneca, Kos Pharmaceuticals, Merck, Merck/Schering-Plough, Pfizer, Inc., Novartis, Reliant
Pharmaceuticals, Inc., Roche Pharmaceuticals, Sankyo Pharma, Sumitomo Pharmaceuticals, and Takeda Pharmaceuticals. He is on the speaker's bureau for Abbott Laboratories, AstraZeneca, Kos Pharmaceuticals, Merck; Merck/Schering-Plough, Pfizer, Inc., Reliant Pharmaceuticals, Inc., Sankyo Pharma, and Takeda Pharmaceuticals. Linda Brookes, MSc
Disclosure: Linda Brookes, MSc, has disclosed no relevant financial
relationships. David Good
Disclosure: David Good has disclosed no relevant financial relationships. Ariana Del Negro
Disclosure: Ariana Del Negro has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
This Activity is sponsored by Medscape Continuing Education Provider Unit. Medscape is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded 1.5 contact hour(s) of continuing nursing education for RNs and APNs; 1.5 contact hours are in the area of pharmacology. Provider Number: 6FDKKC-PRV-05
Contact This Provider
|
|
 Medscape is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Medscape is accredited by the American Council on Pharmacy Education as a provider of continuing pharmacy education. Medscape designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the American Council on Pharmacy Education (Universal Program Number 461-000-08-017-H01-P).
Contact This Provider
|
|
